References
- Feikin DR, Higdon MM, Abu-Raddad LJ, Andrews N, Araos R, Goldberg Y, Groome MJ, Huppert A, O’Brien KL, Smith PG, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. The Lancet. 2022;399:924–10. doi:10.1016/S0140-6736(22)00152-0.
- Dos Santos G, Neumeier E, Bekkat-Berkani R. Influenza - can we cope better with the unpredictable? Hum Vaccin Immunother. 2016;12:699–708. doi:10.1080/21645515.2015.1086047.
- Young M, Crook H, Scott J, Edison P. Covid-19: virology, variants, and vaccines. BMJ Med. 2022;1:e000040. doi:10.1136/bmjmed-2021-000040.
- Buchy P, Badur S. Who and when to vaccinate against influenza. Int J Infect Dis. 2020;93:375–387. doi:10.1016/j.ijid.2020.02.040.
- VRBPAC. Vaccines and Related Biological Products Advisory Committee Meeting. Selection of strain(s) to be included in the periodic updated COVID-19 vaccines for the 2023–2024 vaccination campaign; 2023 Jun 15 [accessed 2023 Jun 21]. https://www.fda.gov/media/169538/download.
- Rosenblum HG, Wallace M, Godfrey M, Roper LE, Hall E, Fleming-Dutra KE, Link-Gelles R, Pilishvili T, Williams J, Moulia DL, et al. Interim recommendations from the advisory committee on immunization practices for the use of bivalent booster doses of COVID-19 vaccines — United States, October 2022. MMWR Morb Mortal Wkly Rep. 2022;71:1436–1441. doi:10.15585/mmwr.mm7145a2.
- Interim recommendations on COVID-19 vaccination in autumn 2022 for the WHO European region. European Technical Advisory Group of Experts on Immunization ad hoc virtual meeting; 2022 Jul 5 [accessed 2023 Jun 21]. https://apps.who.int/iris/handle/10665/359622.
- US Centers for Disease Control and Prevention. Stay up to date with COVID-19 vaccines; 2024 Jan 18 [accessed 2024 Feb 12]. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html.
- US Centers for Disease Control and Prevention. Summary document for interim clinical considerations for use of COVID-19 vaccines currently authorized or approved in the United States; 2023 [accessed 2023 Jun 21]. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html.
- UK Health Security Agency. COVID-19: the green book, chapter 14a; 2023 [accessed 2023 Jun 21]. https://www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a.
- World Health Organization. Expert advisory group recommends COVID-19 vaccination strategy for the autumn season [accessed 2023 Jun 21]. https://www.who.int/europe/news/item/12-07-2022-expert-advisory-group-recommends-covid-19-vaccination-strategy-for-the-autumn-season.
- Australia Government Department of Health and Aged Care. Is it true? Do I have to wait between getting the influenza (flu) and COVID-19 vaccine? [accessed 2023 Apr 8]. https://www.health.gov.au/initiatives-and-programs/covid-19-vaccines/is-it-true/is-it-true-do-i-have-to-wait-between-getting-the-influenza-flu-and-covid-19-vaccine.
- Grohskopf LA, Blanton LH, Ferdinands JM, Chung JR, Broder KR, Talbot HK, Morgan RL, Fry AM. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices — United States, 2022–23 influenza season. MMWR Recomm Rep. 2022;71:1–28. doi:10.15585/mmwr.rr7101a1.
- Canadian immunization guide chapter on influenza and statement on seasonal influenza vaccine for 2022–2023 [accessed 2023 Apr 8]. https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/canadian-immunization-guide-statement-seasonal-influenza-vaccine-2022-2023.html.
- Vaccination INFOservice.Fr [accessed 2023 Apr 8]. https://vaccination-info-service.fr/Les-maladies-et-leurs-vaccins/Grippe.
- Australian Technical Advisory Group on Immunisation (ATAGI). Australian immunisation handbook. Canberra: Australian Government Department of Health; 2022 [accessed 2023 Apr 8]. https://immunisationhandbook.health.gov.au/.
- Centers for Disease Control and Prevention. COVID-19 vaccine and coadministration with other vaccines, 2021 [ accessed 2023 Apr 8]. https://www.cdc.gov/vaccines/hcp/admin/administer-vaccines.html#multiple-injections.
- Naficy A, Kuxhausen A, Pirrotta P, Leav B, Miller J, Anteyi K, Danier J, Breuer T, Mwakingwe-Omari A. No immunological interference or safety concerns when adjuvanted recombinant zoster vaccine is coadministered with a COVID-19 mRNA-1273 booster vaccine in adults aged 50 years and older: a randomized trial. Clin Infect Dis. 2023;77:1238–1246. doi:10.1093/cid/ciad361.
- European Medicines Agency. Spikevax (previously COVID-19 vaccine moderna) [accessed 2023 Apr 8]. https://www.ema.europa.eu/en/medicines/human/EPAR/spikevax.
- US Food & Drug Administration. Emergency use authorization [accessed 2023 Apr 8]. https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#vaccines.
- Graaf H, Faust SN. Fluarix quadrivalent vaccine for influenza. Expert Rev Vaccines. 2015;14:1055–1063. doi:10.1586/14760584.2015.1057573.
- Center for Biologics Evaluation and Research. Guidance for industry clinical data needed to support the licensure of seasonal inactivated influenza vaccines [accessed 2023 Apr 8]. https://www.fda.gov/files/vaccines%2C%20blood%20%26%20biologics/published/Guidance-for-Industry--Clinical-Data-Needed-to-Support-the-Licensure-of-Seasonal-Inactivated-Influenza-Vaccines.pdf.
- Hannoun C, Megas F, Piercy J. Immunogenicity and protective efficacy of influenza vaccination. Virus Res. 2004;103:133–138. doi:10.1016/j.virusres.2004.02.025.
- Corbett KS, Nason MC, Flach B, Gagne M, O’Connell S, Johnston TS, Shah SN, Edara VV, Floyd K, Lai L, et al. Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. Science. 2021;373(6561):eabj0299. doi:10.1126/science.abj0299.
- Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber GR, Dull P, Plotkin SA. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine. 2021;39(32):4423–4428. doi:10.1016/j.vaccine.2021.05.063.
- Bekkat-Berkani R, Wilkinson T, Buchy P, Dos Santos G, Stefanidis D, Devaster JM, Meyer N. Seasonal influenza vaccination in patients with COPD: a systematic literature review. BMC Pulm Med. 2017;17(1):79. doi:10.1186/s12890-017-0420-8.
- Australian Government Therapeutic Goods Administration. Australian public assessment report for influenza virus haemagglutinin proprietary product name: Fluad Quad; 2019 Nov [accessed 2023 Apr 8]. https://www.tga.gov.au/sites/default/files/auspar-influenza-virus-haemagglutinin.pdf.
- Fluarix Quadrivalent Product Information; 2023 Feb [accessed 2023 Apr 8]. https://www.fda.gov/media/79278/download#:~:text=FLUARIX%20QUADRIVALENT%20is%20indicated%20for,aged%206%20months%20and%20older.
- Ji RR, Kohno T, Moore KA, Woolf CJ. Central sensitization and LTP: do pain and memory share similar mechanisms? Trends Neurosci. 2003;26:696–705. doi:10.1016/j.tins.2003.09.017.
- Taddio A, McMurtry CM, Shah V, Riddell RP, Chambers CT, Noel M, MacDonald NE, Rogers J, Bucci LM, Mousmanis P, et al. Reducing pain during vaccine injections: clinical practice guideline. CMAJ. 2015;187(13):975–982. doi:10.1503/cmaj.150391.
- Moro PL, Zhang B, Ennulat C, Harris M, McVey R, Woody G, Marquez P, McNeil MM, Su JR. Safety of co-administration of mRNA COVID-19 and seasonal inactivated influenza vaccines in the vaccine adverse event reporting system (VAERS) during July 1, 2021–June 30, 2022. Vaccine. 2023;41(11):1859–1863. doi:10.1016/j.vaccine.2022.12.069.
- Murdoch L, Quan K, Baber JA, Ho AWY, Zhang Y, Xu X, Lu C, Cooper D, Koury K, Lockhart SP, et al. Safety and immunogenicity of the BNT162b2 vaccine coadministered with seasonal inactivated influenza vaccine in adults. Infect Dis Ther. 2023;12(9):2241–2258. doi:10.1007/s40121-023-00863-5.
- Dulfer EA, Geckin B, Taks EJM, GeurtsvanKessel CH, Dijkstra H, van Emst L, van der Gaast – de Jongh CE, van Mourik D, Koopmans PC, Domínguez-Andrés J, et al. Timing and sequence of vaccination against COVID-19 and influenza (TACTIC): a single-blind, placebo-controlled randomized clinical trial. Lancet Reg Health Eur. 2023;29:100628. doi:10.1016/j.lanepe.2023.100628.
- Lazarus R, Baos S, Cappel-Porter H, Carson-Stevens A, Clout M, Culliford L, Emmett SR, Garstang J, Gbadamoshi L, Hallis B, et al. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdox1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial. The Lancet. 2021;398:2277–2287. doi:10.1016/S0140-6736(21)02329-1.
- Ramsay JA, Jones M, Vande More AM, Hunt SL, Williams PCM, Messer M, Wood N, Macartney K, Lee FJ, Britton WJ, et al. A single blinded, phase IV, adaptive randomised control trial to evaluate the safety of coadministration of seasonal influenza and COVID-19 vaccines (the FluVID study). Vaccine. 2023;41(48):7250–7258. doi:10.1016/j.vaccine.2023.10.050.
- Izikson R, Brune D, Bolduc JS, Bourron P, Fournier M, Moore TM, Pandey A, Perez L, Sater N, Shrestha A, et al. Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study. Lancet Respir Med. 2022;10:392–402. doi:10.1016/S2213-2600(21)00557-9.
- Radner H, Sieghart D, Jorda A, Fedrizzi C, Hasenohrl T, Zdravkovic A, Redlberger-Fritz M, Puchammer-Stoeckl E, Anderle K, Bergmann F, et al. Reduced immunogenicity of BNT162b2 booster vaccination in combination with a tetravalent influenza vaccination: results of a prospective cohort study in 838 health workers. Clin Microbiol Infect. 2023;29:635–641. doi:10.1016/j.cmi.2022.12.008.
- Gonen T, Barda N, Asraf K, Joseph G, Weiss-Ottolenghi Y, Doolman R, Kreiss Y, Lustig Y, Regev-Yochay G. Immunogenicity and reactogenicity of coadministration of COVID-19 and influenza vaccines. JAMA Netw Open. 2023;6(9):e2332813. doi:10.1001/jamanetworkopen.2023.32813.
- Moscara L, Venerito V, Martinelli A, Di Lorenzo A, Toro F, Violante F, Tafuri S, Stefanizzi P. Safety profile and SARS-CoV-2 breakthrough infections among HCWs receiving anti-SARS-CoV-2 and influenza vaccines simultaneously: an Italian observational study. Vaccine. 2023;41(38):5655–5661. doi:10.1016/j.vaccine.2023.07.043.
- Wagenhauser I, Reusch J, Gabel A, Hohn A, Lam TT, Almanzar G, Prelog M, Krone LB, Frey A, Schubert-Unkmeir A, et al. Immunogenicity and safety of coadministration of COVID-19 and influenza vaccination. Eur Respir J. 2023;61:61. doi:10.1183/13993003.01390-2022.
- Toback S, Galiza E, Cosgrove C, Galloway J, Goodman AL, Swift PA, Rajaram S, Graves-Jones A, Edelman J, Burns F, et al. Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial. Lancet Respir Med. 2022;10:167–179. doi:10.1016/S2213-2600(21)00409-4.
- Shenyu W, Xiaoqian D, Bo C, Xuan D, Zeng W, Hangjie Z, Qianhui Z, Zhenzhen L, Chuanfu Y, Juan Y, et al. Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine (CoronaVac) co-administered with an inactivated quadrivalent influenza vaccine: a randomized, open-label, controlled study in healthy adults aged 18 to 59 years in China. Vaccine. 2022;40(36):5356–5365. doi:10.1016/j.vaccine.2022.07.021.
- Chen H, Huang Z, Chang S, Hu M, Lu Q, Zhang Y, Wang H, Xiao Y, Wang H, Ge Y, et al. Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV) coadministered with quadrivalent split-virion inactivated influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in China: a multicentre, non-inferiority, open-label, randomised, controlled, phase 4 trial. Vaccine. 2022;40(36):5322–5332. doi:10.1016/j.vaccine.2022.07.033.